A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: Safety and genital symptom analysis

Toremifene (TOR) is a selective oestrogen receptor modulator (SERM) and has comparable efficacy to that of tamoxifen (TAM) in breast cancer patients. Herein, we compared the safety of TOR to that of TAM in the adjuvant treatment of premenopausal breast cancer.